INFRAPLUS

Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research

Photo credit: NTB

Project Period:
1 June 2024 – 31 May 2027

Grant Agreement:
101131669

Coordinated by INFRAFRONTIER GmbH

Project Description

INFRAPLUS aims to expand INFRAFRONTIER’s capacity for human disease modelling, refine its service portfolio by reducing animal usage and developing alternative cellular models, and optimise the use of resources. INFRAPLUS seeks to achieve several objectives: Developing national node capacities and expertise for providing innovative in vivo, in vitro and preclinical services, developing novel model systems and services to meet the demands of existing and novel user communities, and reducing environmental impact.

To achieve these objectives, INFRAPLUS will focus on launching pilot services, refining new technologies, emphasising alternate cellular models, designing and implementing special training programmes and optimising resources for the entire Consortium. The project includes a defined service development strategy supported by a strong IT and data management backbone and is built upon the needs of the scientific community. Ultimately, INFRAPLUS will enhance and evolve INFRAFRONTIER’s capacity for modelling human diseases and enable breakthrough research by providing researchers cutting-edge tools and services to respond to global biomedical challenges.

INFRAPLUS’s objectives

INFRAPLUS Consortium

13 European countries and Canada
18 institutions

Work Packages

WP

Title

Lead Partner

WP1

Human Disease Modelling using Innovative in vivo Technologies, Models and Services

HMGU & PHENOMIN-ICS

WP2

Development of in vitro Animal Models and Services

Karolinska Institutet & Vetmeduni

WP3

Development of Disease Screens and Evaluation of Preclinical Pipelines

CCP & Alexander Fleming

WP4

Data Management, Enrichment and Analysis

UOulu & CNR

WP5

Enhancing Operational Expertise for Modelling Human Diseases

UKRI

WP6

Animal Welfare, Sustainable Practices and Ethical Considerations

CNB-CSIC

WP7

Dissemination, Exploitation, and Outreach

INFRAFRONTIER GmbH

WP8

Project Coordination & Management

INFRAFRONTIER GmbH

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101131669.

INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).